TW202333676A - 吡唑並〔３，４－ｄ〕嘧啶化合物之固體形式 - Google Patents
吡唑並〔３，４－ｄ〕嘧啶化合物之固體形式 Download PDFInfo
- Publication number
- TW202333676A TW202333676A TW111148528A TW111148528A TW202333676A TW 202333676 A TW202333676 A TW 202333676A TW 111148528 A TW111148528 A TW 111148528A TW 111148528 A TW111148528 A TW 111148528A TW 202333676 A TW202333676 A TW 202333676A
- Authority
- TW
- Taiwan
- Prior art keywords
- solid form
- solid
- temperature
- radiation
- ray powder
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163290136P | 2021-12-16 | 2021-12-16 | |
| US63/290,136 | 2021-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202333676A true TW202333676A (zh) | 2023-09-01 |
Family
ID=85172741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111148528A TW202333676A (zh) | 2021-12-16 | 2022-12-16 | 吡唑並〔３，４－ｄ〕嘧啶化合物之固體形式 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12012412B2 (https=) |
| EP (1) | EP4448529A1 (https=) |
| JP (1) | JP2024546844A (https=) |
| KR (1) | KR20240119299A (https=) |
| CN (1) | CN118401525A (https=) |
| AU (2) | AU2022416644B2 (https=) |
| CA (1) | CA3242577A1 (https=) |
| IL (1) | IL313314A (https=) |
| MX (1) | MX2024007517A (https=) |
| TW (1) | TW202333676A (https=) |
| WO (1) | WO2023114995A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12012412B2 (en) * | 2021-12-16 | 2024-06-18 | Pfizer Inc. | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
| AU2024329573A1 (en) * | 2023-08-22 | 2026-04-02 | Cardurion Pharmaceuticals, Inc. | Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| RS52166B (sr) * | 2007-05-11 | 2012-08-31 | Pfizer Inc. | Amino-heterociklična jedinjenja |
| CN109893653A (zh) * | 2017-12-11 | 2019-06-18 | 王慧敏 | Pde9抑制剂的新用途 |
| US12012412B2 (en) | 2021-12-16 | 2024-06-18 | Pfizer Inc. | Solid forms of pyrazolo[3,4-d]pyrimidine compounds |
-
2022
- 2022-12-16 US US18/082,622 patent/US12012412B2/en active Active
- 2022-12-16 CN CN202280083751.7A patent/CN118401525A/zh active Pending
- 2022-12-16 AU AU2022416644A patent/AU2022416644B2/en active Active
- 2022-12-16 IL IL313314A patent/IL313314A/en unknown
- 2022-12-16 EP EP22854339.3A patent/EP4448529A1/en active Pending
- 2022-12-16 JP JP2024535383A patent/JP2024546844A/ja active Pending
- 2022-12-16 WO PCT/US2022/081795 patent/WO2023114995A1/en not_active Ceased
- 2022-12-16 MX MX2024007517A patent/MX2024007517A/es unknown
- 2022-12-16 TW TW111148528A patent/TW202333676A/zh unknown
- 2022-12-16 CA CA3242577A patent/CA3242577A1/en active Pending
- 2022-12-16 KR KR1020247023041A patent/KR20240119299A/ko active Pending
-
2024
- 2024-05-06 US US18/655,795 patent/US20240300961A1/en active Pending
-
2025
- 2025-12-03 AU AU2025275149A patent/AU2025275149A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007517A (es) | 2024-08-19 |
| AU2022416644A1 (en) | 2024-07-04 |
| NZ812114A (en) | 2025-08-29 |
| AU2025275149A1 (en) | 2026-01-08 |
| CA3242577A1 (en) | 2023-06-22 |
| KR20240119299A (ko) | 2024-08-06 |
| EP4448529A1 (en) | 2024-10-23 |
| CN118401525A (zh) | 2024-07-26 |
| IL313314A (en) | 2024-08-01 |
| JP2024546844A (ja) | 2024-12-26 |
| US12012412B2 (en) | 2024-06-18 |
| US20230192707A1 (en) | 2023-06-22 |
| WO2023114995A1 (en) | 2023-06-22 |
| AU2022416644B2 (en) | 2025-09-11 |
| US20240300961A1 (en) | 2024-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6242460B1 (en) | Zolpidem salt forms | |
| US20240300961A1 (en) | Solid forms of pyrazolo[3,4-d]pyrimidine compounds | |
| JP2017193561A (ja) | ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態 | |
| US8993602B2 (en) | Benzoic acid salt of otamixaban | |
| US12559478B2 (en) | Co-crystal forms of selinexor | |
| EA052651B1 (ru) | ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ | |
| US11136332B2 (en) | Morphic forms of marizomib and uses thereof | |
| US10561667B2 (en) | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor | |
| CN114127074A (zh) | 无定形乌帕拉尼单甲苯磺酸盐 | |
| HK40112450A (zh) | 吡唑并[3，4-d]嘧啶化合物的固体形式 | |
| WO2000058310A1 (en) | Zolpidem salts | |
| TW201908320A (zh) | 一種ｂｔｋ激酶抑制劑的結晶形式及製備方法 | |
| US20240368165A1 (en) | Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate | |
| WO2026024591A1 (en) | Tryptamine prodrug solid forms | |
| WO2026011157A1 (en) | Crystalline forms | |
| HK40119275A (zh) | 新生霉素类似物与脯氨酸的共晶体形式 | |
| CN116947891A (zh) | 一种作为免疫调节剂的联苯类化合物的盐型、晶型及其制备方法 | |
| HK40116055A (zh) | 结构化α-2A肾上腺素受体激动剂的异苯并二氢吡喃-咪唑的新硫酸盐形式 | |
| TW200302830A (en) | Anhydrate/hydrate of an erythromycin derivative and processes for preparing said anhydrate/hydrate | |
| HK40038397B (zh) | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 | |
| WO2019070698A1 (en) | Novel forms of ibrutinib | |
| HK1234747B (zh) | 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型 | |
| KR20060073939A (ko) | 비페프루녹스메실레이트(7-[4-([1,1'-비페닐]-3-일메틸)-1-피페라지닐]-2(3ｈ)-벤즈옥사졸론 모노메탄설포네이트)의 안정한 결정질형태 |